Table 3

Association of IHF1α IHC with clinicopathological variables

NegativePositivep Value
Variables(n=66)(n=213)
Age (median)65650.3571*
Myometrial invasion (median)40250.0646**
Stage
 I39 (59.09)142 (66.67)0.6376
 II10 (15.15)25 (11.74)
 III11 (16.67)32 (15.02)
 IV6 (9.09)14 (6.57)
Tumour size (cm)
 ≤215 (22.73)47 (22.07)1
 >251 (77.27)166 (77.93)
LVI
 No46 (69.7)156 (73.24)0.6367
 Yes20 (30.3)57 (26.76)
Grade_FIGO
 122 (33.33)97 (45.54)0.0231
 29 (13.64)44 (20.66)
 335 (53.03)72 (33.8)
Grade_nuclear
 119 (28.79)74 (34.74)0.0368
 212 (18.18)63 (29.58)
 335 (53.03)76 (35.68)
Lymph node status
 Positive14 (26.92)36 (27.07)1
 Negative38 (73.08)97 (72.93)
Subtype
 CCC+Serous26 (39.39)51 (23.94)0.018
 Endometrioid40 (60.61)162 (76.06)
Recurrence
 No48 (81.36)167 (82.27)0.849
 Yes11 (18.64)36 (17.73)
Status
 ANED40 (60.61)148 (69.48)0.1805
 Others26 (39.39)65 (30.52)
  • *p Value calculated by logistic linear regression.

  • **p Value calculated by Fisher's exact test.

  • ANED, alive with no evidence of disease; FIGO, International Federation of Gynecology and Obstetrics; HIF1α, hypoxia-inducible factor-1α; IHC, immunohistochemical; LVI, lymphovascular invasion.